Previous 10 |
home / stock / bnoef / bnoef news
Bionomics Limited (ASX:BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company leveraging proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates targeting ion channels, is pleased to announce that the Company has accepted an offer from...
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company discovering and developing a pipeline of novel drug candidates targeting ion channels, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation t...
Additional work undertaken on a drug exposure-response analysis shows a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by CAPS-5 at 12 weeks. Bionomics will now seek FDA guidance on next steps for BNC210 for PTSD including the design of a fur...
News, Short Squeeze, Breakout and More Instantly...
Bionomic Ltd Par Ord Company Name:
BNOEF Stock Symbol:
OTCMKTS Market:
Bionomic Ltd Par Ord Website:
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States PR Newswire EASTWOOD, Australia , Jan. 5, 2022 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutica...
Bionomics Limited Announces Pricing of Initial Public Offering in the United States PR Newswire ADELAIDE, Australia , Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutical company, today announced the...
U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders PR Newswire ADELAIDE, Australia , Dec. 1, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) ( Bion...